<?xml version='1.0' encoding='utf-8'?>
<document id="29762875"><sentence text="In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects." /><sentence text="Pomalidomide is an immunomodulatory drug, and the dosage of 4 mg per day taken orally on days 1-21 of repeated 28-day cycles has been approved in the European Union and the United States to treat patients with relapsed/refractory multiple myeloma"><entity charOffset="0-12" id="DDI-PubMed.29762875.s2.e0" text="Pomalidomide" /></sentence><sentence text=" In vitro data showed that pomalidomide is a substrate of multiple cytochrome P450 (CYP) isozymes and that its oxidative metabolism is mediated primarily by CYP1A2 and CYP3A4, with minor contributions from CYP2C19 and CYP2D6"><entity charOffset="27-39" id="DDI-PubMed.29762875.s3.e0" text="pomalidomide" /></sentence><sentence text=" The effect of CYP1A2 inhibition by fluvoxamine (a strong CYP1A2 inhibitor) and CYP1A2 induction by smoking on pomalidomide pharmacokinetics in healthy subjects has been assessed in 2 separate phase 1 open-label, single-dose studies"><entity charOffset="36-47" id="DDI-PubMed.29762875.s4.e0" text="fluvoxamine" /><entity charOffset="111-123" id="DDI-PubMed.29762875.s4.e1" text="pomalidomide" /><pair ddi="false" e1="DDI-PubMed.29762875.s4.e0" e2="DDI-PubMed.29762875.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29762875.s4.e0" e2="DDI-PubMed.29762875.s4.e1" /></sentence><sentence text=" Following administration of a single oral dose of 4 mg pomalidomide, the plasma exposure when coadministered with fluvoxamine was 225"><entity charOffset="56-68" id="DDI-PubMed.29762875.s5.e0" text="pomalidomide" /><entity charOffset="115-126" id="DDI-PubMed.29762875.s5.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.29762875.s5.e0" e2="DDI-PubMed.29762875.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29762875.s5.e0" e2="DDI-PubMed.29762875.s5.e1" /></sentence><sentence text="1% and 123" /><sentence text="7% of that when administered alone for the total plasma exposure (AUC0-inf ) and the plasma peak exposure (Cmax ), respectively" /><sentence text=" In smokers with elevated CYP1A2 activity demonstrated by high caffeine clearance (a marker of CYP1A2 induction), the AUC0-inf was 32"><entity charOffset="63-71" id="DDI-PubMed.29762875.s8.e0" text="caffeine" /></sentence><sentence text="3% lower, whereas the Cmax was 14" /><sentence text="4% higher than that in nonsmokers" /><sentence text=" In addition, pomalidomide was safe and well tolerated as a single oral dose of 4 mg in healthy male smokers and nonsmokers ≥ 40 to ≤ 80 years old, and a single oral dose of 4 mg pomalidomide coadministered with multiple oral 50-mg doses of the CYP1A2 inhibitor fluvoxamine compared with pomalidomide alone was safe and well tolerated by the healthy male subjects"><entity charOffset="14-26" id="DDI-PubMed.29762875.s11.e0" text="pomalidomide" /><entity charOffset="179-191" id="DDI-PubMed.29762875.s11.e1" text="pomalidomide" /><entity charOffset="262-273" id="DDI-PubMed.29762875.s11.e2" text="fluvoxamine" /><entity charOffset="288-300" id="DDI-PubMed.29762875.s11.e3" text="pomalidomide" /><pair ddi="false" e1="DDI-PubMed.29762875.s11.e0" e2="DDI-PubMed.29762875.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29762875.s11.e0" e2="DDI-PubMed.29762875.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29762875.s11.e0" e2="DDI-PubMed.29762875.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29762875.s11.e0" e2="DDI-PubMed.29762875.s11.e3" /><pair ddi="false" e1="DDI-PubMed.29762875.s11.e1" e2="DDI-PubMed.29762875.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29762875.s11.e1" e2="DDI-PubMed.29762875.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29762875.s11.e1" e2="DDI-PubMed.29762875.s11.e3" /><pair ddi="false" e1="DDI-PubMed.29762875.s11.e2" e2="DDI-PubMed.29762875.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29762875.s11.e2" e2="DDI-PubMed.29762875.s11.e3" /></sentence><sentence text="" /></document>